FOLH1 and prostate cancer: Meanwhile, LAVA-1207 was designed to be a γδ bsTCE targeting prostate-specific membrane antigen (PSMA), with its clinical study focusing on metastatic castration-resistant prostate cancer.US-based biotech company IN8bio has also updated positive data from its ongoing phase 1 clinical trial of the allogeneic γδ T cell therapy INB-100 in high-risk AML patients who have previously undergone haploidentical hematopoietic stem cell transplantation (HSCT).